1988
DOI: 10.1007/bf02930830
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of separation and purification processes in the antibiotic industry

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

1989
1989
2023
2023

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 9 publications
0
3
0
Order By: Relevance
“…In biotechnology, to effectively use IL‐based ABS, beforehand experimental work is required to optimize the system parameters so as to ensure a selective extraction of the products of biotechnological interest. Among added‐value metabolites are pharmaceutical drugs, namely antibiotics, and of which tetracyclines (TC) comprise a successful class . TC are a family of polyketide antibiotics produced by Streptomyces genus of actinobacteria .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…In biotechnology, to effectively use IL‐based ABS, beforehand experimental work is required to optimize the system parameters so as to ensure a selective extraction of the products of biotechnological interest. Among added‐value metabolites are pharmaceutical drugs, namely antibiotics, and of which tetracyclines (TC) comprise a successful class . TC are a family of polyketide antibiotics produced by Streptomyces genus of actinobacteria .…”
Section: Introductionmentioning
confidence: 99%
“…Among added-value metabolites are pharmaceutical drugs, namely antibiotics, and of which tetracyclines (TC) comprise a successful class. 35 TC are a family of polyketide antibiotics produced by Streptomyces genus of actinobacteria. 36 TC was first isolated in 1948 37 and differed from the existing antibiotics due to the broad spectrum for antimicrobial activity and low toxicity.…”
Section: Introductionmentioning
confidence: 99%
“…Although there have been efforts and calls to hasten the development of newer antibiotics [ 5 , 6 , 7 ], the discoveries alone could hardly be deemed a panacea for subduing microbes in the “AMR war”. Moreover, the discovery processes, even if eventually successful, are capital-intensive and concurrently less financially rewarding in the contemporary scheme of pervasive microbial adaptations [ 8 , 9 , 10 ]. One revolutionary approach that has “made headlines” in the infectious diseases community is phage therapy [ 11 , 12 , 13 ].…”
Section: Introductionmentioning
confidence: 99%